Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers

Będkowska, Grażyna Ewa; Gacuta, Ewa; Zajkowska, Monika; Głażewska, Edyta Katarzyna; Osada, Joanna; Szmitkowski, Maciej; Chrostek, Lech; Dąbrowska, Milena

doi:10.1186/s13048-017-0338-z

Cited by 19 publications

(30 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased MMP‐9 expression was found to be associated with a poor prognosis, with FIGO (International Federation of Gynecology and Obstetrics) stage, grade of differentiation and LN metastasis in ovarian cancer patients (Li et al, ). Plasma levels of MMP‐7 in combination with commonly accepted tumor markers such as CA125 and HE4 was found to be useful for the diagnosis of epithelial ovarian cancer (EOC) (Simmons et al, ; Bedkowska et al, ) and has also been used in a biomarker panel for early ovarian cancer detection at the point‐of‐care via a multiplexable microfluidic platform (Shadfan et al, ). MMP‐14 and MMP‐2 protein expression is higher in ovarian clear cell carcinoma tissues compared to other ovarian tumor histotypes (serous, endometrioid, mucinous) suggesting that these proteases may contribute to the progression of clear cell carcinomas (Adley et al, ).…”

Section: Diagnosis and Prognosis Of Cancers By Mmpsmentioning

confidence: 99%

Metalloproteinases and their roles in human cancer

Roy

Morad

Jedinak

et al. 2019

The Anatomical Record

View full text Add to dashboard Cite

It is now widely appreciated that members of the matrix metalloproteinase (MMP) family of enzymes play a key role in cancer development and progression along with many of the hallmarks associated with them. The activity of these enzymes has been directly implicated in extracellular matrix remodeling, the processing of growth factors and receptors, the modulation of cell migration, proliferation, and invasion, the epithelial to mesenchymal transition, the regulation of immune responses, and the control of angiogenesis. Certain MMP family members have been validated as biomarkers of a variety of human cancers including those of the breast, brain, pancreas, prostate, ovary, and others. The related metalloproteinases, the A disintegrin and metalloproteinases (ADAMs), share a number of these functions as well. Here, we explore these essential metalloproteinases and some of their disease-associated activities in detail as well as some of their complementary translational potential. Anat Rec, 303:1557-1572, 2020.Matrix metalloproteinases (MMPs) are a multigene family of metal-dependent endopeptidases that play important and diverse roles in normal physiological and pathological processes. The classic domain structure of MMP family members can be found in Figure 1 (Roy et al., 2009). MMPs include an amino-terminal signal peptide required for secretion, a pro-domain that mediates latency via a cysteine-switch mechanism and a Zn 2+ -dependent catalytic domain that is responsible for enzymatic function. A majority of MMPs also contain a C-terminal hemopexinlike domain that provides substrate specificity. MMP activity is the rate-limiting step in extracellular matrix (ECM) degradation and it can regulate the activity of other proteases, growth factors, cytokines, and cell-surface ligands

show abstract

Section: Diagnosis and Prognosis Of Cancers By Mmpsmentioning

confidence: 99%

Metalloproteinases and their roles in human cancer

Roy

Morad

Jedinak

et al. 2019

The Anatomical Record

View full text Add to dashboard Cite

show abstract

“…Early diagnosis of cancer and determination of its stage allows to increase the survival rate of women suffering from breast cancer by indicating effective treatment methods. Due to many reports regarding the usefulness of tumor markers not only in breast cancer, it is very important that the diagnosis is not limited to diagnostic imaging (Lawicki et al, 2013, Będkowska et al, 2017Ławicki et al, 2016;Zajkowska et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

Can VEGFR-3 be a better tumor marker for breast cancer than CA 15-3?

et al. 2020

Self Cite

View full text Add to dashboard Cite

Vascular Endothelial Growth Factor Receptor 3 (VEGFR-3) is a very important factor which promotes lymphangiogenesis not only in physiological but also in pathological processes in which we can include neoplasia. The aim of this study was to analyze the plasma concentrations and diagnostic utility of this parameter in comparison and in combination with CA 15-3 in breast cancer (BC) patients and in relation to the control groups. The study included 120 breast cancer and 60 control patients (28 with benign breast tumors and 32 healthy women). Plasma levels of VEGFR-3 were determined by an Enzyme-Linked Immunosorbent Assay (ELISA), and those of CA 15-3 by a Chemiluminescent Microparticle Immuno Assay (CMIA). Differences in concentrations of both of the tested parameters were statistically significant when breast cancer patients were compared to the control groups. VEGFR-3 had higher values of sensitivity (SE), specificity (SP), predictive value of a positive (PPV) and negative test result (NPV) in the whole BC group (90%; 98.33%; 99.08%; 83.10%, respectively) and, more importantly, in the early stages of BC, than CA 15-3. VEGFR-3 was also a better parameter in terms of statistically significant Area Under Curve (0.9656) in the whole group and at all BC stages (I-IV), but a maximum range was obtained for the combination of VEGFR-3 and CA 15-3 (0.9710). The combined analysis of VEGFR-3 and CA 15-3 provides hope that a new BC diagnostic panel may be developed in the future.

show abstract

“…Early diagnosis and determination of cancer stage allows to increase the survival of patients with breast cancer by indicating effective treatment methods. According to many reports regarding the usefulness of tumor markers not only in breast cancer, it is very important that the diagnosis is not limited to diagnostic imaging (Lawicki et al, 2013;Ławicki et al, 2016;Zajkowska et al, 2016;Będkowska et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

Plasma levels of VEGF-A, VEGF B, and VEGFR-1 and applicability of these parameters as tumor markers in diagnosis of breast cancer

Zajkowska

Lubowicka

Malinowski³

et al. 2018

Acta Biochim Pol

Self Cite

View full text Add to dashboard Cite

The VEGF family members are important factors in promoting angiogenesis and lymphangiogenesis in malignant processes. The aim of this study was to investigate plasma concentrations of VEGF-A, VEGF-B and their soluble VEGFR-1 receptor and their diagnostic utility and potency as compared to CA 15-3 in breast cancer patients and in relation to the control group. The study included 120 breast cancer patients and 60 control patients. Plasma levels of tested parameters were determined with ELISA and CA 15-3 levels were determined with CMIA. Concentrations of all tested parameters in breast cancer patients showed statistically significant difference when compared to the control groups (benign breast tumor patients and/or healthy women). VEGF-B showed the highest values of sensitivity (Sn) and predictive value of a negative test result (NPV) in total BC group (90% and 66.7%, respectively) and, more importantly, in stages I–II of BC (SE: 86.8%; 92.7%, NPV: 82.8%; 88.9%, respectively). Among all parameters tested, VEGF-A showed the highest specificity (Sf) (76.7%) and predictive value of a positive test result (PPV) (84.8%), yet they were lower than for CA 15-3. VEGF-A was also the best parameter that had statistically significant Area Under Curve (AUC) in stages I (0.678) and II (0.768). In the whole group of BC patients all parameters tested showed statistically significant AUC, but the maximum range was obtained for the combination of VEGF-A and CA 15-3 (0.817). The combined analysis of the studied parameters and CA 15-3 resulted in an increase in sensitivity and AUC values, which provides hope for developing a new panel of biomarkers that may be used in BC diagnosis in the future.

show abstract

Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers

Cited by 19 publications

References 46 publications

Metalloproteinases and their roles in human cancer

Metalloproteinases and their roles in human cancer

Can VEGFR-3 be a better tumor marker for breast cancer than CA 15-3?

Plasma levels of VEGF-A, VEGF B, and VEGFR-1 and applicability of these parameters as tumor markers in diagnosis of breast cancer

Contact Info

Product

Resources

About